NASDAQ:ACOR - Acorda Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acorda Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.79 -0.14 (-15.14 %) (As of 04/1/2020 04:00 PM ET) Add Compare Today's Range$0.79Now: $0.79▼$0.9250-Day Range$0.78MA: $1.27▼$2.0152-Week Range$0.70Now: $0.79▼$13.53Volume152,906 shsAverage Volume1.22 million shsMarket Capitalization$37.99 millionP/E RatioN/ADividend YieldN/ABeta1.62 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ACOR Previous Symbol CUSIP00484M10 CIK1008848 Webhttp://www.acorda.com/ Phone914-347-4300Debt Debt-to-Equity Ratio0.78 Current Ratio2.33 Quick Ratio2.04Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$192.41 million Price / Sales0.20 Cash Flow$3.96 per share Price / Cash Flow0.20 Book Value$6.47 per share Price / Book0.12Profitability EPS (Most Recent Fiscal Year)($1.99) Net Income$-272,970,000.00 Net Margins-141.87% Return on Equity-22.18% Return on Assets-9.19%Miscellaneous Employees474 Outstanding Shares48,000,000Market Cap$37.99 million Next Earnings Date5/7/2020 (Estimated) OptionableOptionable Receive ACOR News and Ratings via Email Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ACOR Rates by TradingView Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions How has Acorda Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Acorda Therapeutics' stock was trading at $1.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ACOR stock has decreased by 21.8% and is now trading at $0.7903. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Acorda Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Acorda Therapeutics. When is Acorda Therapeutics' next earnings date? Acorda Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Acorda Therapeutics. How were Acorda Therapeutics' earnings last quarter? Acorda Therapeutics Inc (NASDAQ:ACOR) released its quarterly earnings data on Thursday, February, 13th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.25. The biopharmaceutical company had revenue of $50.50 million for the quarter, compared to analyst estimates of $45.13 million. Acorda Therapeutics had a negative return on equity of 22.18% and a negative net margin of 141.87%. View Acorda Therapeutics' earnings history. What guidance has Acorda Therapeutics issued on next quarter's earnings? Acorda Therapeutics issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, February, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $130-160 million, compared to the consensus revenue estimate of $149.21 million. What price target have analysts set for ACOR? 6 equities research analysts have issued 12 month price targets for Acorda Therapeutics' shares. Their forecasts range from $1.40 to $12.00. On average, they expect Acorda Therapeutics' share price to reach $7.23 in the next twelve months. This suggests a possible upside of 815.3% from the stock's current price. View analysts' price targets for Acorda Therapeutics. What are Wall Street analysts saying about Acorda Therapeutics stock? Here are some recent quotes from research analysts about Acorda Therapeutics stock: 1. Stifel Nicolaus analysts commented, "Stifel analyst Paul Matteis lowered the price target on Acorda Therapeutics, Inc. (NASDAQ: ACOR) to $7.00 (from $12.00) while maintaining a Hold rating." (8/2/2019) 2. According to Zacks Investment Research, "Acorda got a huge boost with the approval of Inbrija in the United States, slightly before the scheduled time period. The drug is also under review in the EU with a decision expected in 2019. Inbrija was launched in February and registered its first sales in the first quarter. Acorda is seeking collaborations on the ex-U.S. commercialization of Inbrija with potential partners both across Europe and Japan. However, its key multiple sclerosis drug Ampyra is facing a generic competition which is significantly hurting Acorda’s top-line. The company expects to see a persistent decline in Ampyra sales during the quarters ahead in 2019. Shares of Acorda have underperformed the industry in the year so far. Nonetheless, Acorda boasts a strong pipeline addressing a wide range of disorders. The restructuring initiative is also saving costs." (7/3/2019) Has Acorda Therapeutics been receiving favorable news coverage? News coverage about ACOR stock has trended very negative on Wednesday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Acorda Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutAcorda Therapeutics. Who are some of Acorda Therapeutics' key competitors? Some companies that are related to Acorda Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Acorda Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include InterDigital Wireless (IDCC), Nektar Therapeutics (NKTR), Applied Materials (AMAT), Gilead Sciences (GILD), Western Digital (WDC), Intel (INTC), Ionis Pharmaceuticals (IONS), Micron Technology (MU), FTS International (FTSI) and Advanced Micro Devices (AMD). Who are Acorda Therapeutics' key executives? Acorda Therapeutics' management team includes the following people: Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 63)Mr. David Lawrence, Chief Technology officer, Chief of Bus. Operations & Principal Accounting Officer (Age 61)Ms. Lauren M. Sabella, Chief Commercial Officer (Age 58)Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 46)Dr. Burkhard Blank, Chief Medical Officer and Head of R&D (Age 64) What is Acorda Therapeutics' stock symbol? Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR." How do I buy shares of Acorda Therapeutics? Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Acorda Therapeutics' stock price today? One share of ACOR stock can currently be purchased for approximately $0.79. How big of a company is Acorda Therapeutics? Acorda Therapeutics has a market capitalization of $37.93 million and generates $192.41 million in revenue each year. The biopharmaceutical company earns $-272,970,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Acorda Therapeutics employs 474 workers across the globe. View additional information about Acorda Therapeutics. What is Acorda Therapeutics' official website? The official website for Acorda Therapeutics is http://www.acorda.com/. How can I contact Acorda Therapeutics? Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300. MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 421 (Vote Outperform)Underperform Votes: 533 (Vote Underperform)Total Votes: 954MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe ACOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACOR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/1/2020 by MarketBeat.com StaffFeatured Article: What is the Shanghai Stock Exchange Composite Index?
